Fennec Pharmaceuticals Inc. (TSE:FRX) Director Rostislav Christov Raykov Sells 2,431 Shares

Fennec Pharmaceuticals Inc. (TSE:FRX) Director Rostislav Christov Raykov sold 2,431 shares of the stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of C$6.13, for a total transaction of C$14,902.03.

Fennec Pharmaceuticals Stock Performance

FRX opened at C$8.16 on Thursday. The company has a debt-to-equity ratio of 1,040.68, a quick ratio of 10.17 and a current ratio of 6.93. The stock has a market capitalization of C$222.93 million, a price-to-earnings ratio of 163.20 and a beta of 0.46. The company has a fifty day moving average of C$10.11 and a 200 day moving average of C$12.47. Fennec Pharmaceuticals Inc. has a fifty-two week low of C$8.16 and a fifty-two week high of C$15.43.

Fennec Pharmaceuticals (TSE:FRX) last issued its quarterly earnings data on Tuesday, May 14th. The biopharmaceutical company reported C$0.56 earnings per share for the quarter, missing analysts’ consensus estimates of C$0.67 by C($0.11). Fennec Pharmaceuticals had a net margin of 6.33% and a negative return on equity of 1,005.59%. The firm had revenue of C$34.21 million for the quarter, compared to analysts’ expectations of C$14.19 million. As a group, sell-side analysts forecast that Fennec Pharmaceuticals Inc. will post 1.1958225 earnings per share for the current fiscal year.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.